Changqing Xie is an Oncology physician affiliated with National Institutes of Health. OpenAlex indexes 69 publications with 1,462 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1562 Opossumtown Pike
Frederick, MD 217024920
Telephone
240-215-6310Provider last certified this registry record 2 Oct 2024.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20251 payment
- Kite Pharma, Inc.Program year20251 payment
- Celgene CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37%PD-1 inhibitor36.8%Pembrolizumab100%Part B, office-administered≥19 patientsGonadotropin Releasing Hormone Receptor Agonist0.2%Leuprolide acetate100%Part B, office-administered≥14 patientsMetabolism & gastrointestinal
31.1%Other antiemetics27%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist4%Granisetron hydrochloride98%Ondansetron Hcl2%Part D + Part B≥53 patients+ 1 more class in this area
Musculoskeletal
15%RANK Ligand Inhibitor14.7%Denosumab100%Part B, office-administered≥35 patientsBisphosphonate0.3%Zoledronic acid100%Part B, office-administered≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Gut Microbiome Controls Liver Tumors via the Vagus Nerve
bioRxiv (Cold Spring Harbor Laboratory)
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Greten, MD
National Institutes of Health
Joel Moss, MD
National Institutes of Health
Lynnette Nieman, MD
National Institutes of Health
Steven Pavletic, MD
National Institutes of Health
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”